A third of the most popular cancer treatment articles on social media contained misinformation. (Huntsman Cancer Institute, Journal of the National Cancer Institute)
The FDA issued a safety alert about the recently approved multiple myeloma drug melphalan flufenamide (Pepaxto), following the deaths of two patients enrolled in a confirmatory clinical trial. MedPage Today has the details.
Bristol Myers Squibb announced that it has voluntarily withdrawn its FDA-approved indication for nivolumab (Opdivo) for hepatocellular carcinoma previously treated with sorafenib (Nexavar).
Incyte received a complete response letter from the FDA stating that the agency needs additional data before considering approval of the PD-1 inhibitor retifanlimab for previously treated advanced squamous cell cancer of the anal canal.
The Canadian Nuclear Safety Commission launched a study to determine the incidence of lung cancer among workers in the uranium mining, milling, and processing industry. (Canada’s National Observer)
Merck announced that continued follow-up in the KEYNOTE-355 trial showed statistically significant improvement in overall survival in patients with unresectable/metastatic triple-negative breast cancer and PD-L1 expression ≥10%.
Survival improvement in childhood and adolescent cancers has not been consistent across all types of malignancies. (Cancer)
Most older women with breast cancer might be candidates for genetic testing. (Mayo Clinic, Journal of Clinical Oncology)
Artificial intelligence used to evaluate cancer images takes analytical shortcuts that can bias results for minority patients. (University of Chicago Medical Center, Nature Communications)
Mount Sinai Health System in New York established a program that specializes in care for men and women who carry BRCA cancer predisposition genes.
The American Society for Radiation Oncology adopted a new clinical guideline for use of radiation therapy in the management of localized soft-tissue sarcoma in adults. (Practical Radiation Oncology)
A healthy lifestyle may help offset the adverse effects of genetics on cancer risk. (American Association for Cancer Research)